The cyclic arginine glycine aspartic acid (cRGD) tripeptide for targeting integrin αvβ3 over-expressed cancer cells and a caspase-3 enzyme specific Asp-Glu-Val-Asp (DEVD) peptide were combined to construct the prodrug. The gene discussed is CASP3; the disease is cancer.